Abbott, AstraZeneca to co-develop combination pill for lipid management

By Lisa Kerner

Charlotte, N.C., July 5 - Abbott and AstraZeneca are co-developing and marketing a combination pill targeting three blood lipids, LDL-C (bad cholesterol), HDL-C (good cholesterol) and triglycerides.

Under their agreement, the companies will begin two parallel programs: a Crestor (rosuvastatin calcium)/TriCor (fenofibrate tablets) fixed-dose combination and a Crestor/ABT-335 combination.

Based on the trial results, one of the two programs will be selected for final development and commercialization.

"This collaboration has the potential to provide physicians and patients with the first statin and fibrate combination in a single pill to comprehensively manage lipids," Abbott vice president of global pharmaceutical clinical development Eugene Sun said in a company news release.

Abbott and AstraZeneca will share development costs and profits, with Abbott responsible for the clinical trial program and regulatory registration.

AstraZeneca will hold the New Drug Application.

Abbott develops pharmaceuticals and medical products, including nutritionals, devices and diagnostics.

AstraZeneca is an international health care business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and health care services.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.